Association of low potassium diet and folic acid deficiency in patients with CKD

Kamal Hassan1,2
1Faculty of Medicine in the Galilee, Bar-Ilan University, Safed, 2Department of Nephrology and Hypertension, Peritoneal Dialysis Unit, Galilee Medical Center, Nahariya, Israel

Background: Most of the folic acid sources are rich also in potassium. Patients with chronic kidney disease (CKD) usually receive a low potassium diet. We investigated the possibility of an association between low potassium diet and folic acid deficiency.

Methods: In total, 128 CKD patients participated in this cross-sectional study. Sixty-four patients with CKD grades 1 and 2 were on an unrestricted potassium diet when enrolled in the study, and 64 patients with CKD grades 3 and 4 had received instructions to restrict their intake of potassium at least 6 months before enrollment in the study. Subjects were evaluated for daily intake of folic acid (DI_FA), daily intake of potassium (DI_K), and serum folic acid levels (S_FA).

Results: DI_FA correlated with the estimated glomerular filtration rate, the DI_K, and the S_FA (P<0.001). S_FA correlated with the estimated glomerular filtration rate (P<0.001). Mean DI_FA and mean S_FA were lower among patients with CKD grades 3 and 4 than among those with CKD grades 1 and 2 (P<0.001). The mean DI_FA in patients with folic acid deficiency was lower than that in those with S_FA ≥7.1 nmol/L (P<0.001). There was lower S_FA and threefold greater frequency of folic acid deficiency among patients with CKD grades 3 and 4 who had received instructions to restrict their intake of potassium than among patients with CKD grades 1 and 2 who were on an unrestricted potassium diet.

Conclusion: A potassium-restricted diet offered to patients with CKD grades 3 and 4 may be associated with folic acid deficiency. Serum levels of folic acid should be investigated before starting potassium restriction in patients with CKD grades 3 and 4, in order to identify individuals with folic acid deficiency or with marginal serum levels who should receive folic acid replacement therapy.

Keywords: chronic kidney disease, folic acid, low potassium diet

Introduction

Folic acid is a water-soluble vitamin that is present in green leafy vegetables, such as spinach, chard, kale, sprouts, zucchini, beans, and asparagus, as well as in tomatoes, mushrooms, sweet potatoes, bananas, avocado, and citrus fruits and juices. Folic acid is also found in shellfish, kidney, and liver. The normal daily requirement of folic acid is 200–400 μg. Because folic acid is not stored in the fat tissues of the body, its serum levels may decrease after only a few weeks of eating a diet low in vegetables and fruits. Mild folic acid deficiency is usually asymptomatic, but in more severe deficient states, tongue soreness, diarrhea, headaches, weakness, forgetfulness, and fatigue may develop. Folic acid deficiency may produce megaloblastic anemia, congenital neurological defects, and an increased risk of breast, pancreatic, and colon cancer. It has also been considered a risk factor for coronary artery disease. Serum folic acid tests are routinely ordered in the assessment of anemia, dementia, and altered mental status. The prevalence of folic acid deficiency varies in different parts of...
the world and depends on nutritional status, dietary habits, and alcohol consumption.\textsuperscript{14,15}

Most folic acid sources are also rich in potassium. Although folic acid deficiency may develop in people with diseases that affect absorption in the gastrointestinal tract (such as celiac disease and Crohn’s disease) and those who overuse alcohol, consistently consume overcooked vegetables, or use certain medicines (such as phenytoin, sulfasalazine, or trimethoprim-sulfamethoxazole), the main cause of folic acid deficiency is still a diet low in vegetables and fruits rich in folic acid.

Patients with chronic kidney disease (CKD) grades 3 and 4 usually receive instructions to restrict their dietary potassium intake in order to prevent development of hyperkalemia. To the best of our knowledge, the impact of a low potassium diet on daily folic acid intake and serum folic acid levels remains to be determined. The aim of the present study was to investigate the possibility of an association between low potassium diet and folic acid deficiency in CKD patients.

Patients and methods
This cross-sectional study was conducted in the outpatient clinic at the Department of Nephrology, Galilee Medical Center, Nahariya, Israel, and included a convenience sample of 128 CKD patients. The study was approved by the ethics committee of Galilee Medical Center, Nahariya, Israel, and Clalit Health Services, Israel. All patients signed a written informed consent form before participating in the study. Inclusion criteria were: 40–65 years of age and CKD grades 1–4. Exclusion criteria were: celiac disease, gastrointestinal malignancy, chronic diarrhea or vomiting, previous gastrointestinal surgery; consumption of a particular diet, eg, vegetarian; psychiatric orders; pregnancy; and treatment with vitamin B12 supplementation or medicines that may affect serum folic acid.

Glomerular filtration rate (GFR) was calculated according to the Chronic Kidney Disease Epidemiology Collaboration equation.\textsuperscript{16} Of the 128 study participants, 33 had CKD grade 1 (estimated GFR $\geq$90 mL/min), 31 had CKD grade 2 (estimated GFR 60–89 mL/min), 32 had CKD grade 3 (estimated GFR 30–59 mL/min), and 32 had CKD grade 4 (estimated GFR 15–29 mL/min). Of these, 64 patients with CKD grade 1 or 2 (CKD 1–2 group, with estimated GFR $\geq$60 mL/min) were on an unrestricted potassium diet when enrolled in the study, and 64 patients with CKD grade 3 or 4 (CKD 3–4 group, with estimated GFR <60 mL/min) had received instructions to restrict their intake of potassium at least 6 months before enrollment in the study.

All patients included in the study were evaluated for daily potassium intake by an experienced, well-trained dietary interviewer who instructed respondents to describe all foods and beverages they consumed. Only patients who adhered to the low potassium diet when requested to do so were included in the study.

Participants were evaluated for daily intake of folic acid and serum levels of folic acid by a dietitian using specific questionnaires from surveys and studies of nutrition and dietary consulting. The Israeli recommended daily folic acid intake is 400 μg/day. Serum levels of folic acid lower than 7.1 nmol/L were defined as folic acid deficiency, since this is the lowest limit of normalcy in the laboratory in which folic acid was analyzed for our patients.

Statistical methods
Quantitative variables were described using the mean and standard deviation. Qualitative variables were described using frequencies and percentages. Pearson’s correlation coefficient test was used to describe associations between daily dietary folic acid intake, serum folic acid levels, and estimated GFR. Analysis of variance, chi-square test, Kruskal–Wallis test, and independent-samples t-test were used to compare variables between study groups. P-values less than 0.05 were considered to be statistically significant. Analyses were carried out using Statistical Package for the Social Sciences version 19 software (SPSS Inc, Chicago, IL, USA).

Results
The study included 128 participants, of whom 65 (50.8%) were men. The mean age overall was 57.2±6.7 (range 41–65) years. The age and sex distribution, as well as the proportion with diabetes, was similar between the four groups according to CKD grade (Tables 1 and 2).

Mean 24-hour proteinuria was lowest in patients with CKD grade 1, highest in patients with CKD grade 4 ($P<0.001$, Table 1), and higher in the CKD 3–4 group than in the CKD 1–2 group ($P<0.001$, Table 2). The mean serum potassium level was lowest in patients with CKD grade 1, highest in patients with CKD grade 4 ($P<0.01$, Table 1), and higher in the CKD 3–4 group than in the CKD 1–2 group ($P<0.001$, Table 2). The mean hemoglobin level was highest in patients with CKD grade 1, lowest in patients with CKD grade 4, and lower in the CKD 3–4 group than in the CKD 1–2 group ($P<0.001$, Tables 1 and 2). Mean daily potassium intake was highest in patients with CKD grade 1, lowest in patients with CKD grade 4, and lower in
the CKD 3–4 group than in the CKD 1–2 group ($P<0.001$, Tables 1 and 2).

In analysis of all the participants together, the daily intake of folic acid correlated with estimated GFR ($r=-0.52$, $P<0.001$, Pearson’s correlation coefficient test, Figure 1) and with serum folic acid levels ($r=0.66$, $P<0.001$, Pearson’s correlation coefficient test, Figure 2). Serum levels of folic acid correlated with estimated GFR ($r=-0.65$, $P<0.001$, Pearson’s correlation coefficient test, Figure 3).

Mean daily intake of folic acid and mean serum folic acid levels were lower among patients with CKD grades 3 and 4 than among those with CKD grades 1 and 2 ($P<0.001$, Table 3). The mean daily intake of folic acid in patients with folic acid deficiency was lower than in those with serum folic acid levels $\geq 7.1$ mmol/L ($P<0.001$, Figure 4). Lower serum folic acid levels and a threefold greater frequency of folic acid deficiency were found in patients with CKD grades 3 and 4 who had received instructions to restrict their intake of potassium than in patients with CKD grades 1 and 2 who were on an unrestricted potassium diet (Table 3). Daily intake of folic acid correlated with daily potassium intake (Pearson coefficient correlation test, $r=0.79$, $P<0.001$, Figure 5).

### Discussion

Based on the Food and Nutrition Center of the Institute of Medicine and the report of the Dietary Guidelines Advisory Committee on Dietary Guidelines for Americans, the daily recommended dietary potassium intake for adults is 4.7 g. This amount of intake contributes to maintaining lower blood pressure levels, reducing the risk of developing kidney stones, and possibly decreasing bone loss.\(^{17,18}\)

In a population with normal kidney function, a potassium intake from food that exceeds 4.7 g/day poses no potential for increased risk because excess potassium is readily excreted in the urine. However, a potassium intake below 4.7 g/day is indicated for individuals whose urinary potassium excretion is impaired, such as in CKD or end-stage renal disease.\(^{17,18}\)

Although a low potassium diet, not infrequently recommended to patients with CKD grades 3 and 4, can prevent development of hyperkalemia, its impact on serum levels of folic acid is not clear. Whether these patients should receive folic acid replacement therapy also remains to be determined. Moreover, clinical folic acid deficiencies are relatively rare, and most patients are far more likely to have

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Baseline characteristics of the study population</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CKD 1</td>
</tr>
<tr>
<td>Total, n % (n)</td>
<td>25.8 (33)</td>
</tr>
<tr>
<td>DM, n %</td>
<td>48.5 (16)</td>
</tr>
<tr>
<td>Age (years)</td>
<td>57.8±5.0</td>
</tr>
<tr>
<td>Males, n %</td>
<td>48.5 (16)</td>
</tr>
<tr>
<td>Females, n %</td>
<td>51.5 (17)</td>
</tr>
<tr>
<td>Estimated GFR (mL/min)</td>
<td>105.8±11.6</td>
</tr>
<tr>
<td>24-hour proteinuria</td>
<td>404.9±226.5</td>
</tr>
<tr>
<td>Serum potassium (mEq/L)</td>
<td>4.5±0.4</td>
</tr>
<tr>
<td>Daily potassium intake (g/day)</td>
<td>4.8±0.6</td>
</tr>
<tr>
<td>Hemoglobin (g/dl)</td>
<td>13.6±1.0</td>
</tr>
</tbody>
</table>

Notes: Values are presented as mean±standard deviation unless otherwise stated. *Analysis of variance; **chi-square test.

Abbreviations: CKD, chronic kidney disease; DM, diabetes mellitus; GFR, glomerular filtration rate.

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Baseline characteristics of the study groups</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CKD 1–2</td>
</tr>
<tr>
<td>Total, n % (n)</td>
<td>50.0 (64)</td>
</tr>
<tr>
<td>DM, n %</td>
<td>48.4 (31)</td>
</tr>
<tr>
<td>Age (years)</td>
<td>57.6±6.4</td>
</tr>
<tr>
<td>Males, n %</td>
<td>50.0 (32)</td>
</tr>
<tr>
<td>Females, n %</td>
<td>50.0 (32)</td>
</tr>
<tr>
<td>Estimated GFR (mL/min)</td>
<td>90.8±18.2</td>
</tr>
<tr>
<td>24-hour proteinuria</td>
<td>458.8±286.9</td>
</tr>
<tr>
<td>Serum potassium (mEq/L)</td>
<td>4.6±0.4</td>
</tr>
<tr>
<td>Daily potassium intake (g/day)</td>
<td>4.7±0.6</td>
</tr>
<tr>
<td>Hemoglobin (g/dl)</td>
<td>13.7±1.1</td>
</tr>
</tbody>
</table>

Notes: Values are presented as mean±standard deviation unless otherwise stated. *Independent samples t-test; **chi-square test.

Abbreviations: CKD, chronic kidney disease; DM, diabetes mellitus; GFR, glomerular filtration rate.
subclinical folic acid deficiency. The main finding of this study is lower serum folic acid levels and a threefold greater frequency of folic acid deficiency among patients with CKD grades 3 and 4, who were on a potassium-restricted diet, than among patients with CKD grades 1 and 2, who were not on a potassium-restricted diet. Another important finding is the correlation between daily intake of folic acid and serum folic acid levels.

The prevalence of folic acid deficiency varies around the world, and mainly depends on dietary status. Since folic acid is not stored in the human body, a diet low in vegetables and fruits may lead to a deficient state within a few weeks. While mild-to-moderate folic acid deficiency is usually asymptomatic or may be associated with weakness, fatigue, and forgetfulness, more severe states may produce hematological and neuropsychiatric complications, increase the risk of some malignancies, and contribute to coronary artery disease. In this cross-sectional study, folic acid deficiency was asymptomatic in all deficient patients. However, identifying these individuals and treating them with folic acid replacement therapy seems to be essential to prevent development of the serious complications associated with severe and prolonged folic acid deficiency.

The anemia of CKD is principally due to reduced production of renal erythropoietin and, to a lesser degree, to shortened survival of red cells and decreased responsiveness to the hormone. Other possible causes of anemia in patients with CKD include iron deficiency, inflammation, folic acid and vitamin B12 deficiencies, and accumulation of uremic toxins.

**Table 3** Daily folic acid intake, serum folic acid levels, and prevalence of folic acid deficiency in CKD grades 3 and 4 group compared with CKD grades 1 and 2 group

<table>
<thead>
<tr>
<th>Variables</th>
<th>CKD 1–2 (n=64)</th>
<th>CKD 3–4 (n=64)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>DI, μg/day</td>
<td>352.4±76.6</td>
<td>248.1±68.8</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>S, nmol/L</td>
<td>19.0±1.7</td>
<td>8.9±3.4</td>
<td>&lt;0.001*</td>
</tr>
<tr>
<td>S&lt;7.1 nmol/L (%)</td>
<td>6.1</td>
<td>19.7</td>
<td>0.01**</td>
</tr>
</tbody>
</table>

**Notes**: Values are presented as mean ± standard deviation unless otherwise stated. *Independent-samples t-test; **chi-square test.

**Abbreviations**: DI, daily intake of folic acid; S, serum levels of folic acid; CKD, chronic kidney disease.
toxins. Anemia is common in patients with CKD as GFRs decline to <60 mL/min/1.73 m². In the present study, no significant effect of folic acid on hemoglobin levels was detected, possibly due to the numerous factors that contribute to development of renal anemia.

Cardiovascular complications are considered the major cause of morbidity and mortality in CKD patients. The role of folic acid supplementation on development of cardiovascular complications is still controversial. While some studies and meta-analyses indicate that folic acid supplementation does not reduce cardiovascular morbidity or mortality in patients with CKD, other meta-analyses suggest that folic acid replacement therapy can reduce cardiovascular risk in this population. In one meta-analysis, which included 8,234 patients with CKD from nine randomized trials using folic acid therapy, the results indicate that folic acid supplementation may be effective for prevention of cardiovascular disease in CKD patients. In another meta-analysis, which included 3,886 patients from seven randomized trials using folic acid therapy, it was concluded that folic acid therapy reduces the risk of cardiovascular disease by 15% in patients with advanced CKD. In a third meta-analysis, which included 2,052 subjects from ten randomized trials using folic acid therapy, it was concluded that, folic acid supplementation reduced progression of atherosclerosis as measured by carotid intima media thickness. Moreover, folic acid supplementation may offer a renal protective effect against oxidative stress.

Although there is no consensus regarding the impact of folic acid supplementation on development of cardiovascular complications, folic acid deficiency may still produce other considerable clinical disturbances (eg, hematological, neuropsychiatric, and malignant disorders) and therefore should be detected and treated.

The main cause of folic acid deficiency is low dietary intake. Usually, patients with CKD grade 3 or 4 are advised to consume a low potassium diet. Because most sources of folic acid are rich in potassium, adherence to such a diet may reduce folic acid intake. Thus, the serum levels of folic acid may be inversely affected when patients with CKD grades 3 and 4 adhere to instructions that restrict their potassium intake.

CKD patients usually have a number of risk factors that may affect their well-being, health, and survival. They include traditional risk factors (ie, diabetes mellitus, dyslipidemia, hypertension, and cigarette smoking), uremia (ie, fluid overload, phosphorus accumulation, vascular calcifications, anemia, hyperparathyroidism, and hyperhomocysteinemia) and novel risk factors (ie, inflammation, oxidative stress, and endothelial dysfunction) that contribute to morbidity and mortality in patients suffering from renal insufficiency.

Only a few studies have evaluated the influence of a low potassium diet on serum levels of folic acid in CKD patients. One study reported that folic acid levels in diabetic CKD patients were compared with those in controls. The results of the present study reveal that lower serum folic acid levels
and a threefold greater frequency of folic acid deficiency were found in patients with CKD grades 3 and 4 who were on a potassium-restricted diet. We suppose that the lower dietary folic acid intake in patients with CKD grades 3 and 4 than in patients with CKD grades 1 and 2 was due to adherence to lower potassium intake in the former. Folic acid deficiency may further contribute to substantial clinical consequences in CKD patients. However, this study did not include comparison groups of patients with CKD grades 1 and 2 who restricted their potassium intake, or patients with CKD grades 3 and 4 who did not restrict their potassium intake, since such treatment would not be congruent with current medical guidelines. The evidence is thus currently not sufficient to recommend without reservation folic acid replacement therapy for all CKD patients on restricted low potassium diets. However, based on the results of the present study, we suggest that serum levels of folic acid should be investigated before starting potassium restriction in all patients with CKD grades 3 and 4, in order to identify individuals with folic acid deficiency or with marginal serum levels who should receive folic acid replacement therapy. Serum levels of folic acid should subsequently be monitored periodically in patients on a low potassium diet.

**Limitations**

The present study was conducted in one medical center and included a relatively small number of patients. Additional and larger multicenter, randomized controlled trials are needed to establish the prevalence of folic acid deficiency and need for replacement therapy in CKD patients on a low potassium diet.

**Conclusion**

The potassium-restricted diet offered to patients with CKD grades 3 and 4 may be associated with folic acid deficiency. Serum levels of folic acid should be investigated before starting potassium restriction in all patients with CKD grades 3 and 4 patients, in order to identify individuals with folic acid deficiency or with marginal serum levels who should receive folic acid replacement therapy.

**Disclosure**

The author reports no conflicts of interest in this work.

**References**


